Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications PR Newswire - Tue Nov 4, 6:30AM CST

-  New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab

ATNM : 1.2550 (-3.46%)
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference PR Newswire - Mon Nov 3, 7:30AM CST

NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies,...

ATNM : 1.2550 (-3.46%)
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire - Mon Oct 27, 6:00AM CDT

-  ATNM-400 exhibits superior efficacy with 3-5x greater tumor growth inhibition compared to front line therapy osimertinib (EGFR TKI TAGRISSO ® ), second line therapy Dato-DXd (Trop-2 ADC DATROWAY...

ATNM : 1.2550 (-3.46%)
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat PR Newswire - Fri Oct 24, 7:30AM CDT

- ATNM-400 targets a novel, non-PSMA antigen implicated in disease biology with continued expression following androgen receptor pathway inhibitor (ARPI) therapy and 177Lu-PSMA-617 therapy,...

ATNM : 1.2550 (-3.46%)
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire - Mon Oct 13, 11:10AM CDT

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever...

ATNM : 1.2550 (-3.46%)
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat PR Newswire - Mon Oct 13, 7:30AM CDT

-   ATNM-400 targets a highly differentiated, non-PSMA antigen associated with the development and progression of prostate cancer, exhibiting potent therapeutic activity independent of PSMA expression...

ATNM : 1.2550 (-3.46%)
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit PR Newswire - Thu Jul 31, 7:30AM CDT

-     ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto ® and enzalutamide, follow-up continues

ATNM : 1.2550 (-3.46%)
Investors Bet on Biotech as Public Cancer Research Hits a Wall BayStreet.ca - Thu Jun 26, 9:16AM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – As cancer rates continue to climb worldwide, the race to develop better, faster, and more affordable treatments...

ONCY : 1.0850 (-4.41%)
AGEN : 4.28 (-3.39%)
OLMA : 8.02 (-0.50%)
ICCM : 0.7100 (+0.31%)
ONC.TO : 1.42 (+2.16%)
ATNM : 1.2550 (-3.46%)
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz Newswire.ca - Mon Apr 14, 9:10AM CDT

/CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...

ONCY : 1.0850 (-4.41%)
ONC : 370.42 (-1.87%)
CVM : 6.66 (-1.19%)
ONC.TO : 1.42 (+2.16%)
ATNM : 1.2550 (-3.46%)
OSTX : 1.8500 (-3.65%)
Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements FinancialNewsMedia - Thu Mar 27, 7:30AM CDT

EQNX::TICKER_START (NYSE:ATNM),(NYSE:BMY),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AZN) EQNX::TICKER_END

AZN : 88.78 (+1.25%)
LLY : 1,026.12 (+0.82%)
NVS : 132.15 (-0.11%)
ATNM : 1.2550 (-3.46%)
BMY : 49.08 (+0.09%)

Barchart Exclusives

As Momentum Slows for Rigetti Computing, Should You Sell RGTI Stock Here? Barchart - 2 minutes ago
Rigetti shares extend losses as mixed Q3 earnings continue to weigh on sentiment. Benchmark recommends that investors be opportunistic buyers on further weakness in RGTI stock. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot